XML 29 R18.htm IDEA: XBRL DOCUMENT v3.26.1
LOSS PER SHARE APPLICABLE TO COMMON STOCKHOLDERS
 3 Months Ended
Mar. 31, 2026
Earnings Per Share [Abstract]  
LOSS PER SHARE APPLICABLE TO COMMON STOCKHOLDERS

NOTE 10 - LOSS PER SHARE APPLICABLE TO COMMON STOCKHOLDERS

 

Basic net loss per common share (“Basic EPS”) is computed by dividing net loss available to common stockholders by the weighted average number of common shares outstanding during the period. All outstanding stock options and warrants for the three months ended March 31, 2026, and 2025 have been excluded from the calculation of the diluted net loss per share because all such securities are anti-dilutive for all periods presented.

 

The following table sets forth the computation of the net loss per share for the period presented:

 

         
   Three Months Ended March 31, 
   2026   2025 
Numerator:  $   $ 
Net loss   (3,822)   (1,872)
Dividend on Series X Preferred Stock   (623)   - 
Dividend on Series H Preferred Stock   (236)   - 
Deemed dividend for down round on Series H Preferred Stock (See note 7)   (16,974)   - 
Deemed contribution on extinguishment of Series X Preferred Stock   131      
Deemed dividend on modification of Series H Preferred Stock (See note 7)   (1,097)   - 
Net loss available to common stockholders  $(22,621)  $(1,872)

 

 

ENVUE MEDICAL, INC.

Notes to the Interim Condensed Consolidated Financial Statements (unaudited)

(Amounts in thousands except share and per share data)

 

The following table summarizes the Company’s securities, in common stock equivalents, which have been excluded from the calculation of dilutive loss per share as their effect would be anti-dilutive:

 

   March 31, 2026   March 31, 2025 
Stock options - employee and non-employee  $4,411   $4,505 
Warrants   1,145,436    18,440 
Total  $1,149,847   $22,945 

 

The diluted loss per share equals basic loss per share for the three months ended March 31, 2026, and 2025 because the Company had a net loss and the impact of the assumed exercise of stock options and the vesting of restricted stock would have been anti-dilutive.